Use of Clopidogrel and Proton Pump Inhibitors Alone or in Combinations in Persons with Diabetes in Denmark; Potential for CYP2C19 Genotype-Guided Drug Therapy

Use of Clopidogrel and Proton Pump Inhibitors Alone or in Combinations in Persons with Diabetes in Denmark; Potential for CYP2C19 Genotype-Guided Drug Therapy

Background: Clopidogrel and proton pump inhibitors (PPIs) are among the most used drugs in Denmark for which there exists pharmacogenomics (PGx)-based dosing guidelines and FDA annotations. In this study, we further scrutinized the use of clopidogrel and PPIs when prescriptions were redeemed from Da...

Full description

Bibliographic Details
Main Authors: Niels Westergaard, Lise Tarnow, Charlotte Vermehren
Format: Article
Language:English
Published: MDPI AG 2021-02-01
Series:Metabolites
Subjects:
clopidogrel
proton pump inhibitors (PPIs)
drug use
pharmacogenomics
polypharmacy
drug–drug interactions
Online Access:https://www.mdpi.com/2218-1989/11/2/96

Similar Items

Similar Items